Rebus Holdings Inc (RBSH)

[abazaba375]

$NSPX ~ DD March 29th 2020

Share Structure

Market Cap Market Cap 116,117 03/27/2020
Authorized Shares 150, 000, 000
Outstanding Shares 11,383,983 12/01/2019

https://www.otcmarkets.com/stock/NSPX/security

LINK to companys Twitter~ https://twitter.com/InspyrTheraputx

Recent Financial statements ~ https://fintel.io/so/us/nspx


CHARTS

$NSPX @ c Elliot Wave 2 on the five way up fractal .05-.10 next week pic.twitter.com/e2kmNJuELh

— TweetVestor3 (@TVestor3) March 28, 2020

RECENT NEWS


https://microcapdaily.com/the-inside-scoop-on-inspyr-therapeutics-inc-otcmkts-nspx/125607/

These Companies Are High Potential Game Changers For COVID-19 Treatments & Vaccines
Mar. 27, 2020 1:20 PM ET

Inspyr Therapeutics (OTCPK:NSPX)

Inspyr Therapeutics is an integrated clinical-stage biopharmaceutical company that is focused on developing targeted cancer therapeutics for the treatment of cancerous tumors, including breast, prostate, bladder, kidney, and lung cancer along with the development of novel therapies to treat cancer, inflammation, and other serious diseases.

Inspyr, like Gilead's Remdesivir utilizes similar targeting of adenosine for a novel COVID-19 treatment. Inspyr merged with Lewis and Clark Pharmaceuticals several years ago and since then has developed a proprietary, industry-leading technology platform based on adenosine chemistry and biology and a broad pipeline of novel therapies. Their pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist.

While developing new A2A and A2B adenosine antagonists as well as dual A2A/A2B adenosine antagonist with improved drug like properties resulting in better bioavailability for the treatment of:

• Cancer• Asthma• Diabetes

Broad pipeline of novel therapies for oncology and inflammation.

· Lewis and Clark’s pipeline of novel proprietary therapies includes four lead programs: a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. These therapies are highly potent and selective, with important molecular properties that enable enhanced distribution in tissue and penetration of human skin. These therapies are in advanced preclinical development.

· The dual A2A/A2B antagonist has both immune function modulation and anti-angiogenic properties and thus has potential as an immuno-oncology and anti-angiogenic agent to treat multiple types of solid and hematological malignancies.

· The A2A agonists offers the potential to treat inflammatory and autoimmune diseases as arthritis, Crohn’s disease, diabetic nephropathy, and psoriasis.

· The A2B antagonist offers the potential to treat asthma, type 2 diabetes, atherosclerosis, and nonalcoholic fatty liver disease.

Inspyr’s lead therapy, Mipsagargin, currently is in development for the treatment of solid tumors.

1. For liver cancer, Mipsagargin in combination with Nexavar® is being evaluated in a preclinical study in liver tumor models that express different levels of PSMA, the target of Mipsagargin. Inspyr is finalizing the design of a clinical study to examine the potential benefits of Mipsagargin in combination with Nexavar® in patients with advanced hepatocellular carcinoma (HCC), or liver cancer.

2. For gastric cancer, Inspyr has initiated a preclinical study in gastric cancer tumor models that express different levels of PSMA. In this initial study, Mipsagargin will be evaluated first in combination with paclitaxel and in a subsequent study will be evaluated in combination with DC101 (Cyramza® surrogate antibody).

3. Utilizing Lewis and Clark’s wet laboratory facilities, Inspyr has the potential to internally develop additional pro-drugs targeting PSMA with different toxic payloads.

A potential cancer killer not in the commercial markets yet.

In addition to their cutting-edge therapies, Inspyr’s board of directors have extensive experience along with strong ties to Pfizer (PFE), Glaxo Smith Kline (GSK), Exelixis (EXEL), and Astellas Pharma (OTCPK:ALPMF). In previous years, Inspyr Therapeutics (formerly GenSpera) has raised tens of millions in equity funding, received millions in grants, and on 1/21/20, leading hedge fund Shabby Management LLC and their associated funds announced an ownership stake of nearly 40% in NSPX.

Then on 3/6/20, Inspyr filed an 8-K with the SEC in that the company sold an aggregate of $250,000 of senior convertible debentures ("Debentures") for cash to existing accredited institutional investors of the Company (the "Offering") with an original set conversion price was $0.33.

Looking at the recent surge in volume and the share price of NSPX over the past few days, it’s reason to think there is some serious correlation connecting the funds behind Inspyr, recent disclosures, their extensive patent portfolio, and the proprietary technology and drugs they have that can be quickly repurposed to treat and possibly cure this new novel coronavirus COVID-19 and put an end to this global pandemic.

In conclusion, these companies all seem quite promising right now in the fight against COVID-19 not just as a virus but the havoc it has wrecked on the US and world economies. Currently, this novel coronavirus does not seem to be letting up and continues to spread worldwide. If these companies all win, we all win, together. Whether they all are used in expanded commercial use efforts and/or there are partnerships, mergers or acquisitions – whatever is necessary to expand efforts should be explored, if not already.

Utilizing advanced technology platforms, AI, and delivery systems with old repurposed drugs and/or in combination new ones could provide the cure the world needs. These are some of the most promising companies that can get us there.

PRESS RELEASE


Inspyr Therapeutics: Can This High Potential Cancer Killing Biotech Repurpose Drugs to Help Fight COVID-19?
Published: Mar 24, 2020 9:15 a.m. ET

https://www.marketwatch.com/press-release/inspyr-therapeutics-can-this-high-potential-cancer-killing-biotech-repurpose-drugs-to-help-fight-covid-19-2020-03-24

https://finance.yahoo.com/news/ahf-demands-gilead-drop-exclusive-170400234.html


https://seekingalpha.com/instablog/50574163-forex-in-world/5426392-companies-are-high-potential-game-changers-for-covidminus-19-treatments-vaccines

https://www.morningstar.com/stocks/pinx/nspx/valuation

Hedge Fund Sabby management owns 40% of the OS here https://twitter.com/vonklein300/status/1242590230156197888?s=20
https://fintel.io/i/sabby-management-llc

$NSPX since taking a position in $AYTU the stock has risen 800 % since March 12th NSPX has dollar potential pic.twitter.com/nPZegIP76W

— TweetVestor3 (@TVestor3) March 28, 2020

https://www.crunchbase.com/organization/genspera#section-overview
NSPX has raised 22 million dollars.

NOW to quote power battles point why are we hearing buyout talks ?

Recently they just hire Michael Cain for Interim CEO. about 90% interim CEO last for 90% why The company has been quiet for years now all suddenly hire interim CEO? Why all suddenly the analyst new ratings Inspyr Therapeutics Inc. BUY target $21.75? Why people keep spreading the buyout rumor? These questions remain unanswered but one thing I can assure you that base one billion dollar value thapsigargin put us worth no less than 6.66 buyout per share and that is the low end because they do have multi billion dollar asset.

what if NSPX is putting these anonymous news releases out from third parties as a direct negotiating tactic to to drive the price of a potential buyout up ?? to me If your following theres a 96 k note that sabby has already renegotiated to march 31st is a day to circle and could be the reason the price spike buyout rumours have been circling big time. The 96 k note which im reffereingto based on the last few days volume would take 20 minutes to be eaten up.
maybe SAbby came to the table with a low ball effort knowing they only need 10 % more to gain more then 50% of the os and essentially the company. and NSPX started to put out these news releeases to drive the negotaitions ?? hmmmmm big week ahead me thinks